Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria – A Model for Mosquito-Borne Diseases
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking to fund research aimed at accelerating the development of highly effective vaccines against malaria and potentially other mosquito-borne diseases. This initiative emphasizes innovative vaccine design strategies, such as structure-based immunogen design and combination vaccines, to either prevent parasite infection or significantly reduce the disease burden associated with malaria. The contract supports basic research, discovery, and preclinical development phases, targeting next-generation vaccine technologies. The opportunity is forecasted under the authority granted by Sections 301 and 405 of the Public Health Service Act and relevant federal regulations. The effort is managed by the National Institutes of Health within the Department of Health and Human Services. Interested parties can contact the designated team via the provided email to obtain further details. This contract highlights a strategic focus on leveraging recent technological advances to address a major global health challenge through innovative vaccine solutions.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to support basic research, discovery, and/or preclinical development of highly efficacious vaccines for malaria and potentially other mosquito-borne illness. The program will encourage novel approaches to vaccine design that capitalize on recent technological innovations including structure-based immunogen design, and/or combination vaccines to reduce parasite infection and/or reduce malaria disease burden. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
